McKesson (MCK) Q2 2027 Earnings Call Transcript

McKesson reported fiscal Q2 revenue of $111.0 billion, up 8%, and adjusted EPS of $11.68, up 18% year over year. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40 from $44.20–$45.00, citing first-half performance; management said growth excluding specified prior-year items implies 19%–21%. The company completed its $2.25 billion Precision Medicine Group acquisition, agreed to invest $1.4 billion for a 49% stake in Option Care Health, and repurchased $3.4 billion of shares in the first half, while noting branded-drug pricing and Medical-Surgical product mix headwinds.

Analysis

MCK: the more durable signal is operating leverage in distribution and specialty—not headline revenue, which is sensitive to drug list-price resets and mixes high-volume, low-margin activity with higher-value services. But the EPS beat is not wholly repeatable: repurchases are boosting per-share growth, the quarter included a discrete tax benefit, and prior-year comparison gains complicate segment optics. The raised outlook is a positive near-term catalyst; the tougher test is sustaining profit growth as investment spending ramps and GLP-1 prior-authorization volumes normalize.

Over 1–3 months, watch RxTS growth and operating profit, North American Pharmaceutical profit conversion, and management commentary on 340B implementation. A rebate model could shift working-capital and administrative burdens onto covered entities, changing ordering behavior; MCK’s broad channel exposure may cushion script movement, but does not guarantee unchanged economics. CVS’s long renewal reduces near-term customer-retention uncertainty for MCK while preserving CVS’s scale as a counterparty with negotiating leverage.

The 6–18 month thesis depends on converting Precision Medicine Group’s clinical-research and market-access capabilities into cross-selling and eventual earnings—not simply achieving management’s accretion estimates. The Option Care Health stake is strategic exposure to home infusion, but is a minority investment, not immediate operating control or a current MCK segment-growth driver. MedSurg separation execution and related financing remain additional sources of complexity. Contrarian read: strong growth may obscure mix and capital-return dependence; conversely, GLP-1 revenue deceleration alone would not disprove MCK’s broader specialty-volume thesis. No valuation data are supplied, so avoid an unconditional chase.

Key Decisions for Investors

• MCK: favor a staged long on post-earnings consolidation rather than chasing the initial reaction. Reassess if North American Pharmaceutical operating-profit growth materially slows or RxTS profit trends weaken as prior-authorization volumes normalize.
• Treat CVS’s extension as reducing MCK customer-renewal risk, not as evidence of improved pricing power. Monitor contract economics and any signs of customer concentration or service-cost pressure before expressing a relative-value trade.
• OPCH: keep on a catalyst watchlist around shareholder and regulatory approvals and deal closing. The strategic stake may support the growth narrative, but do not price in operating synergies or a future control transaction without evidence.
• Over the next 1–3 months, verify 340B rule details, MCK cash conversion and buyback pace, and MedSurg separation financing. A materially adverse policy implementation, weaker cash generation, or separation cost escalation would challenge the constructive MCK view.